Cell Therapy Manufacturing Market

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Cell-based Therapies
3.2.1. Comparison of Cell-based Therapies and Other Biotechnological Products
3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
3.2.3. Current Market Landscape of ATMPs

3.3. Overview of Cell Therapy Manufacturing
3.4. Cell Therapy Manufacturing Models
3.4.1. Centralized Manufacturing
3.4.2. Decentralized Manufacturing
3.5. Scalability of Cell Therapy Manufacturing Processes
3.5.1. Scale-up
3.5.2. Scale-out

3.6. Types of Cell Therapy Manufacturers
3.7. Key Challenges for Manufacturing Cell Therapies
3.8. Key Factors Influencing Cell Therapy Manufacturing
3.8.1. Characterization
3.8.2. Cost of Goods
3.9. Automation of Cell Therapy Manufacturing Processes
3.10. Cell Therapy Manufacturing Supply Chain
3.11. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. Cell Therapy Manufacturing (Industry Players): Overall Market Landscape
4.2.1. Analysis by Company Size
4.2.2. Analysis by Year of Establishment
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Year of Establishment and Location of Headquarters
4.2.6. Analysis by Location of Manufacturing Facility
4.2.7. Analysis by Type of Manufacturer
4.2.8. Analysis by Location of Headquarters and Type of Manufacturer

4.2.9. Analysis by Type of Cell Manufactured
4.2.10. Analysis by Company Size and Type of Cell Manufactured
4.2.11. Analysis by Location of Headquarters and Type of Cell Manufactured
4.2.12. Analysis by Source of Cells
4.2.13. Analysis by Type of Cell Manufactured and Source of Cells
4.2.14. Analysis by Scale of Operation
4.2.15. Analysis by Manufacturing Capabilities / Services Offered
4.2.16. Analysis by Company Size and Services Offered
4.2.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered

4.3. Cell Therapy Manufacturing (Non-Industry Players): Overall Market Landscape
4.3.1. Analysis by Organization Size
4.3.2. Analysis by Year of Establishment
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Organization Size and Location of Headquarters
4.3.5. Analysis by Year of Establishment and Location of Headquarters
4.3.6. Analysis by Location of Manufacturing Facility
4.3.7. Analysis by Type of Manufacturer
4.3.8. Analysis by Location of Headquarters and Type of Manufacturer

4.3.9. Analysis by Type of Cell Manufactured
4.3.10. Analysis by Organization Size and Type of Cell Manufactured
4.3.11. Analysis by Location of Headquarters and Type of Cell Manufactured
4.3.12. Analysis by Source of Cells
4.3.13. Analysis by Type of Cell Manufactured and Source of Cells
4.3.14. Analysis by Scale of Operation
4.3.15. Analysis by Manufacturing Capabilities / Services Offered
4.3.16. Analysis by Organization Size and Services Offered
4.3.17. Analysis by Year of Establishment, Location of Headquarters and Services Offered

5. REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory Guidelines in North America
5.2.2. Regulatory Guidelines in Europe
5.2.3. Regulatory Guidelines in Japan
5.2.4. Regulatory Guidelines in China
5.2.5. Conditional Approvals

5.3. Regulatory Accreditations for Cell Therapy Manufacturing
5.3.1. Facilities Approved by Regulators to Manufacture Cell Therapies
5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies
5.5. Existing Challenges to Clinical-Stage Manufacturing of Cell Therapies
5.5.1. Variability in Regulatory Guidelines across Different Geographies

6. ROADMAPS FOR OVERCOMING CHALLENGES
6.1. Chapter Overview
6.2. Roadmap for the US
6.2.1. Cell Processing
6.2.2. Cell Preservation, Distribution and Handling
6.2.3. Process Automation and Data Analytics
6.2.4. Process Monitoring and Quality Control
6.2.5. Standardization and Regulatory Support
6.2.6. Workforce Development
6.2.7. Supply Chain and Logistics
6.3. Roadmaps for Other Geographies
6.3.1. Europe
6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
7.1. Chapter Overview
7.2. Automation of Cell Therapy Manufacturing Processes
7.2.1. Closed Systems
7.2.2. Single-use Systems
7.2.3. Modular Systems
7.3. Growth Drivers and Roadblocks
7.4. Case Studies
7.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
7.4.2. Automating the Cell Therapy Manufacturing Process
7.5. GMP-in-a-Box
7.6. List of Automated and Closed Cell Therapy Processing Systems
7.7. Comparative Analysis of Manual and Automated Processes

8. PROFILES: INDUSTRY PLAYERS
8.1. Chapter Overview
8.2. Service Providers in North America
8.2.1 AGC Biologics
8.2.1.1. Company Overview
8.2.1.2. Service Portfolio
8.2.1.3. Manufacturing Facilities and Capabilities
8.2.1.4. Recent Developments and Future Outlook

8.2.2. Charles River Laboratories
8.2.2.1. Company Overview
8.2.2.2. Service Portfolio
8.2.2.3. Manufacturing Facilities and Capabilities
8.2.2.4. Recent Developments and Future Outlook

8.2.3. KBI Biopharma
8.2.3.1. Company Overview
8.2.3.2. Service Portfolio
8.2.3.3. Manufacturing Facilities and Capabilities
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Thermo Fisher Scientific
8.2.4.1. Company Overview
8.2.4.2. Service Portfolio
8.2.4.3. Manufacturing Facilities and Capabilities
8.2.4.4. Recent Developments and Future Outlook

8.3. Service Providers in Europe
8.3.1. BioNTech Innovative Manufacturing Services
8.3.1.1. Company Overview
8.3.1.2. Service Portfolio
8.3.1.3. Manufacturing Facilities and Capabilities
8.3.1.4. Recent Developments and Future Outlook

8.3.2. Cell and Gene Therapy Catapult
8.3.2.1. Company Overview
8.3.2.2. Service Portfolio
8.3.2.3. Manufacturing Facilities and Capabilities
8.3.2.4. Recent Developments and Future Outlook

8.3.3. Lonza
8.3.3.1. Company Overview
8.3.3.2. Service Portfolio
8.3.3.3. Manufacturing Facilities and Capabilities
8.3.3.4. Recent Developments and Future Outlook

8.3.4. RoslinCT
8.3.4.1. Company Overview
8.3.4.2. Service Portfolio
8.3.4.3. Manufacturing Facilities and Capabilities
8.3.4.4. Recent Developments and Future Outlook

8.4. Service Providers in Asia Pacific
8.4.1. Cell Therapies
8.4.1.1. Company Overview
8.4.1.2. Service Portfolio
8.4.1.3. Manufacturing Facilities and Capabilities
8.4.1.4. Recent Developments and Future Outlook

8.4.2. FUJIFILM Cellular Dynamics
8.4.2.1. Company Overview
8.4.2.2. Service Portfolio
8.4.2.3. Manufacturing Facilities and Capabilities
8.4.2.4. Recent Developments and Future Outlook

8.4.3. Minaris Regenerative Medicine
8.4.3.1. Company Overview
8.4.3.2. Service Portfolio
8.4.3.3. Manufacturing Facilities and Capabilities
8.4.3.4. Recent Developments and Future Outlook

8.4.4. MEDINET
8.4.4.1. Company Overview
8.4.4.2. Service Portfolio
8.4.4.3. Manufacturing Facilities and Capabilities
8.4.4.4. Recent Developments and Future Outlook

8.4.5. Nikon CeLL Innovation
8.4.5.1. Company Overview
8.4.5.2. Service Portfolio
8.4.5.3. Manufacturing Facilities and Capabilities
8.4.5.4. Recent Developments and Future Outlook

8.4.6. WuXi AppTec
8.4.6.1. Company Overview
8.4.6.2. Service Portfolio
8.4.6.3. Manufacturing Facilities and Capabilities
8.4.6.4. Recent Developments and Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS
9.1. Chapter Overview
9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
9.2.1. Overview
9.2.2. Operating Segments
9.2.3. Service Portfolio
9.2.4. Manufacturing Facilities and Capabilities

9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
9.3.1. Overview
9.3.2. Service Portfolio
9.3.3. Manufacturing Facilities and Capabilities

9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
9.4.1. Overview
9.4.2. Service Portfolio
9.4.3. Manufacturing Facilities and Capabilities

9.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
9.5.1. Overview
9.5.2. Service Portfolio
9.5.3. Manufacturing Facilities and Capabilities

9.6. Laboratory for Cell and Gene Medicine, Stanford University
9.6.1. Overview
9.6.2. Service Portfolio
9.6.3. Manufacturing Facilities and Capabilities

9.7. Molecular and Cellular Therapeutics, University of Minnesota
9.7.1. Overview
9.7.2. Service Portfolio
9.7.3. Manufacturing Facilities and Capabilities

9.8. Newcastle Cellular Therapies Facility, Newcastle University
9.8.1. Overview
9.8.2. Service Portfolio
9.8.3. Manufacturing Facilities and Capabilities

9.9. Rayne Cell Therapy Suite, King’s College London
9.9.1. Overview
9.9.2. Manufacturing Facilities and Capabilities

9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
9.10.1. Overview
9.10.2. Manufacturing Facilities and Capabilities

9.11. Sydney Cell and Gene Therapy
9.11.1. Overview
9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS
10.1. Chapter Overview
10.2. Cell Therapy Manufacturing: Non-Profit Organizations
10.2.1. CellCAN
10.2.2. Cell Therapy Manufacturing Cooperative Research Center
10.2.3. National Cell Manufacturing Consortium (NCMC)
10.2.4. California Institute of Regenerative Medicine (CIRM)
10.3. Cell Therapy Manufacturing: International Societies

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Cell Therapies: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Registration Year and Trial Status
11.4.5. Analysis by Trial Phase
11.4.6. Analysis of Enrolled Patient Population Trial Phase
11.4.7. Analysis by Type of Sponsor / Collaborator
11.4.8. Analysis by Patient Segment
11.4.9. Analysis by Study Design
11.4.10. Most Active Players: Analysis by Number of Registered Trials
11.4.11. Analysis by Number of Trials and Geography
11.4.12. Analysis by Number of Trials, Trial Status and Geography
11.4.13. Analysis by Enrolled Patient Population, Trial Status and Geography

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models

12.3. Cell Therapy Manufacturing: List of Partnerships
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership

12.4. Analysis by Type of Cell Manufactured

12.5. Analysis by Scale of Operation

12.6. Analysis by Region
12.6.1. Continent-wise Distribution
12.6.2. Country-wise Distribution

12.7. Most Active Players: Analysis by Number of Partnerships

12.8. Cell Therapy Manufacturing: List of Mergers and Acquisitions
12.8.1. Analysis by Year of Agreement
12.8.2. Analysis by Type of Agreement
12.8.3. Analysis by Year of Acquisition and Type of Cell Manufactured
12.8.4. Analysis by Region
12.8.4.1. Continent-wise Distribution
12.8.4.2. Country-wise Distribution
12.8.4.3. Intercontinental and Intracontinental Deals
12.8.5. Ownership Change Matrix

13. RECENT EXPANSIONS
13.1. Chapter Overview
13.2. Cell Therapy Manufacturing: List of Expansions
13.2.1. Cumulative Year-wise Distribution
13.2.2. Analysis by Type of Expansion
13.2.3. Analysis by Types of Cells Manufactured
13.2.4. Analysis by Scale of Operation
13.2.5. Analysis by Location of Manufacturing Facility
13.2.6. Analysis by Type of Expansion and Location of Manufacturing Facility
13.2.7. Most Active Players: Analysis by Number of Expansions
13.2.8. Most Active Players: Analysis by Area of Expansion
13.2.9. Analysis by Year and Location of Manufacturing Facility

14. BIG PHARMA INITIATIVES
14.1. Chapter Overview
14.2. Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
14.2.1. Analysis by Number of Initiatives
14.2.2. Analysis by Year of Initiative
14.2.3. Analysis by Type of Initiative
14.2.3.1. Analysis by Type of Partnership
14.2.3.2. Analysis by Type of Expansion

14.2.4. Analysis by Types of Cells Manufactured
14.2.5. Analysis by Scale of Operation
14.2.6. Analysis of Big Pharma Players by Year of Initiative
14.2.7. Analysis by Year and Type of Initiative
14.2.8. Analysis of Big Pharma Players by Types of Cells Manufactured
14.2.9. Analysis of Big Pharma Players by Scale of Operation

14.3. Competitive Benchmarking of Big Pharmaceutical Players
14.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
14.3.2. Spider Web Analysis: Big Pharmaceutical Players

15. CAPACITY ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology (Industry Players)
15.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
15.2.1.1. Analysis by Company Size
15.2.1.2. Analysis by Scale of Operation
15.2.1.3. Analysis by Location of Manufacturing Facility
15.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
15.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility

15.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
15.2.2.1. Analysis by Company Size
15.2.2.2. Analysis by Scale of Operation
15.2.2.3. Analysis by Location of Manufacturing Facility
15.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
15.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility

15.3. Key Assumptions and Methodology (Non-Industry Players)
15.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
15.3.1.1. Analysis by Scale of Operation
15.3.1.2. Analysis by Location of Manufacturing Facility
15.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
15.3.2.1. Analysis by Scale of Operation
15.3.2.2. Analysis by Location of Manufacturing Facility
15.4 Concluding Remarks

16. DEMAND ANALYSIS
16.1 Chapter Overview
16.2 Scope and Methodology
16.3 Global Demand for Cell Therapy Manufacturing
16.4 Global Clinical Demand for Cell Therapy Manufacturing
16.4.1. Analysis by Type of Cell Therapy
16.4.2. Analysis by Geography
16.5. Global Commercial Demand for Cell Therapy Manufacturing
16.5.1. Analysis by Type of Cell Therapy
16.5.2. Analysis by Geography

17. COST PRICE ANALYSIS
17.1. Chapter Overview
17.2. Factors Contributing to the High Price of Cell Therapies
17.3. Pricing Models for Cell Therapies
17.3.1. Based on Associated Costs for T-Cell Therapies
17.3.2. Based on Associated Costs for Stem Cell Therapies
17.3.3. Based on Availability of Competing Products
17.3.4. Based on Target Patient Segment
17.3.5. Based on the Opinions of Industry Experts
17.4. Cell Therapy Cost Optimization
17.4.1. Role of Cost of Goods Sold
17.4.2. Role of Automation
17.5. Role of Cell Therapy Contract Manufacturing Organizations
17.6. Reimbursement-related Considerations for Cell Therapies
17.6.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

18. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
18.1. Chapter Overview
18.2. Assumptions and Key Parameters
18.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
18.3.1. Scenario 1
18.3.2. Scenario 2
18.3.3. Scenario 3
18.3.4. Scenario 4
18.4. Concluding Remarks

19. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS
19.1. Chapter Overview
19.2. Key Parameters
19.3. Assumptions and Methodology
19.4. Sample Dataset for the Estimation of Total Cost of Ownership
19.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
19.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
19.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
19.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

20. MARKET SIZING AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope of the Forecast
20.3. Input Data and Key Assumptions
20.4. Forecast Methodology
20.5. Global Cell Therapy Manufacturing Market, 2022-2035
20.5.1. Cell Therapy Manufacturing Market: Analysis by Type of Cell Therapy, 2022-2035
20.5.2. Cell Therapy Manufacturing Market: Analysis by Source of Cells, 2022-2035
20.5.3. Cell Therapy Manufacturing Market: Analysis by Scale of Operation, 2022-2035
20.5.4. Cell Therapy Manufacturing Market: Analysis by Purpose of Manufacturing, 2022-2035 
20.5.5. Cell Therapy Manufacturing Market: Analysis by Region, 2022-2035

20.6. Cell Therapy Manufacturing Market for Commercial Scale Manufacturing
20.6.1. Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035
20.6.1.1. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
20.6.1.2. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.1.3. Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region

20.6.2. Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035
20.6.2.1. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.2.2. Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region

20.6.3. Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
20.6.3.1. Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035: Analysis by Region
20.6.4. Global Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
20.6.4.1. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
20.6.4.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region

20.7. Cell Therapy Manufacturing Market for Clinical Scale Manufacturing
20.7.1. Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035
20.7.1.1. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Type of Therapy
20.7.1.2. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.1.3. Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035: Analysis by Region

20.7.2. Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
20.7.2.1. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.2.2. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2022-2035: Analysis by Region

20.7.3. Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035
20.7.3.1. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.3.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035: Analysis by Region

20.7.4. Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
20.7.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Source of Cells
20.7.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Analysis by Region

21. KEY INSIGHTS
21.1. Chapter Overview
21.2. Cell Therapy Manufacturing: Grid Analysis
21.3. Cell Therapy Manufacturing: Logo Landscape
21.3.1. Immune Cell Therapy Manufacturing: Logo Landscape
21.3.2. Stem Cell Therapy Manufacturing: Logo Landscape
21.4. Cell Therapy Manufacturing: World Map Representation based on Location of Manufacturing Facilities
21.4.1. Industry Players
21.4.2. Non-Industry Players

22. SWOT ANALYSIS
22.1. Chapter Overview
22.2. Strengths
22.3. Weaknesses
22.4. Opportunities
22.5. Threats
22.6. Comparison of SWOT Factors

23. CONCLUDING REMARKS
23.1. Chapter Overview

24. SURVEY ANALYSIS
24.1. Chapter Overview
24.2. Analysis by Designation of Respondents
24.3. Analysis by Type of Cell Therapy
24.4. Analysis by Scale of Operation
24.5. Analysis by Source of Cells
24.6. Analysis by Type of Cell Culture System Used
24.7. Analysis by Availability of Fill / Finish Services

25. INTERVIEW TRANSCRIPTS
25.1. Chapter Overview
25.2. RoslinCT
25.2.1. Company Overview
25.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer

25.3. Discovery Life Sciences
25.3.1. Company Overview
25.3.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell and Gene Therapy

25.4. Glycostem Therapeutics
25.4.1. Company Overview
25.4.2. Interview Transcript: Troels Jordansen, Chief Executive Officer

25.5. Bio Elpida
25.5.1. Company Overview
25.5.2. Interview Transcript: Gilles Devillers, President

25.6. Gracell Biotechnologies
25.6.1. Company Overview
25.6.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer

25.7. Kadimastem
25.7.1. Company Overview
25.7.2. Interview Transcript: Arik Hasson, Executive VP Research and Development

25.8. RoslinCT
25.8.1. Company Overview
25.8.2. Interview Transcript: Fiona Bellot, Ex-Business Development Manager

25.9. University of Minnesota
25.9.1. Company Overview
25.9.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine

25.10. Lion TCR
25.10.1. Company Overview
25.10.2. Interview Transcript: Victor Lietao Li, Ex- Co-Founder and Chief Executive Officer

25.11. Center for Commercialization of Cancer Immunotherapy / C3i
25.11.1. Company Overview
25.11.2. Interview Transcript: Arnaud Deladeriere, Ex-Manager, Business Development & Operations-cGMP Manufacturing Unit

25.12. Waisman Biomanufacturing
25.12.1. Company Overview
25.12.2. Interview Transcript: Brian Dattilo, Manager of Business Development

25.13. Yposkesi
25.13.1. Company Overview
25.13.2. Interview Transcript: Mathilde Girard, Ex-Department Leader, Cell Therapy Innovation and Development

25.14. Cell Therapies
25.14.1. Company Overview
25.14.2. Interview Transcript: Tim Oldham, Ex-Chief Executive Officer

25.15. CiMaas
25.15.1. Company Overview
25.15.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer 

26. APPENDIX 1: TABULATED DATA27. APPENDIX

27: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Mergers and Acquisitions
Figure 2.5 Executive Summary: Recent Expansions
Figure 2.6 Executive Summary: Big Pharma Initiatives
Figure 2.7 Executive Summary: Capacity Analysis
Figure 2.8 Executive Summary: Demand Analysis
Figure 2.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 3.2 Decentralized Manufacturing: Process Model
Figure 3.3 Cell Therapy Manufacturing: Type of Manufacturers
Figure 3.4 Cell Therapies: Key Challenges and Drivers
Figure 3.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 3.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 4.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Figure 4.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Figure 4.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Location of Headquarters
Figure 4.6 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment and Location of Headquarters
Figure 4.7 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 4.8 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 4.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Figure 4.10 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Figure 4.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 4.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.14 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Type of Cell Manufactured
Figure 4.15 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 4.16 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Figure 4.17 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured and Source of Cells
Figure 4.18 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Figure 4.19 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 4.20 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Services Offered
Figure 4.21 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Figure 4.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size
Figure 4.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment
Figure 4.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Figure 4.25 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Figure 4.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Figure 4.27 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment and Location of Headquarters
Figure 4.28 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Figure 4.29 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.30 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Figure 4.31 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Figure 4.32 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured
Figure 4.33 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 4.34 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 4.35 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Type of Cell Manufactured
Figure 4.36 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 4.37 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Figure 4.38 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cell Manufactured and Source of Cells
Figure 4.39 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Figure 4.40 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Figure 4.41 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Services Offered
Figure 4.42 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Figure 5.1 Cell Therapy Manufacturing (Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities / Certifications
Figure 5.2 Cell Therapy Manufacturing (Non-Industry Players): Distribution of Manufacturing Facilities by Regulatory Authorities / Certifications
Figure 7.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 7.2 Pre-Requisites for Implementing Closed Systems in Cell Therapy Manufacturing Processes
Figure 7.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 7.4 Advantages and Disadvantages Associated with Single-Use Systems
Figure 7.5 Growth Drivers and Roadblocks Related to the Adoption of Automated and Closed Systems
Figure 7.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 7.7 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes
Figure 7.8 Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Affiliated Costs
Figure 8.1 AGC Biologics: Service Portfolio
Figure 8.2 Charles River Laboratories: Service Portfolio
Figure 8.3 KBI Biopharma: Service Portfolio
Figure 8.4 Thermo Fisher Scientific: Service Portfolio
Figure 8.5 BioNTech Innovative Manufacturing Services: Service Portfolio
Figure 8.6 Cell and Gene Therapy Catapult: Services
Figure 8.7 Lonza: Business Divisions
Figure 8.8 Lonza: Historical Timeline
Figure 8.9 Lonza: Service Portfolio
Figure 8.10 Lonza: Biological Manufacturing Services
Figure 8.11 Lonza: Cell-based Products
Figure 8.12 RoslinCT: Service Portfolio
Figure 8.13 Cell Therapies: Service Portfolio
Figure 8.14 FUJIFILM Cellular Dynamics: Service Portfolio
Figure 8.15 Minaris Regenerative Medicine: Service Portfolio
Figure 8.16 MEDINET: Service Portfolio
Figure 8.17 Nikon CeLL Innovation: Service Portfolio
Figure 8.18 WuXi AppTec: Service Portfolio
Figure 9.1 Center for Cell and Gene Therapy: Operating Segments
Figure 9.2 Center for Cell and Gene Therapy: Service Portfolio
Figure 9.3 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 9.4 Clinical Cell and Vaccine Production Facility: Service Portfolio
Figure 9.5 Guy’s and St Thomas’ GMP Facility: Service Portfolio
Figure 9.6 Laboratory for Cell and Gene Medicine: Service Portfolio
Figure 9.7 Molecular and Cellular Therapeutics: Service Portfolio
Figure 9.8 Newcastle Cellular Therapies Facility: Service Portfolio
Figure 9.9 Rayne Cell Therapy Suite, King’s College London: Service Portfolio
Figure 9.10 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Center for Regenerative Medicine: Service Portfolio
Figure 9.11 Sydney Cell and Gene Therapy: Service Portfolio
Figure 11.1 Clinical Trial Analysis: Scope and Methodology
Figure 11.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2022
Figure 11.3 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2022
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 11.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.7 Clinical Trial Analysis: Distribution of Number of Trials by Enrolled Patient Population and Trial Phase
Figure 11.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 11.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 11.10 Clinical Trial Analysis: Distribution by Study Design
Figure 11.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 11.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 11.13 Clinical Trial Analysis: Distribution by Number of Trials and Geographical Location
Figure 11.14 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Figure 11.15 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 12.4 Partnerships and Collaborations: Distribution by Type of Cells
Figure 12.5 Heat Map: Distribution by Year and Type of Cells
Figure 12.6 Partnerships and Collaborations: Distribution by Type of T-Cells
Figure 12.7 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 12.8 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 12.9 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Figure 12.10 Partnerships and Collaborations: Country-wise Distribution
Figure 12.11 Partnerships and Collaborations: Continent-wise Distribution
Figure 12.12 Most Active Players: Distribution by Number of Partnerships
Figure 12.13 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022
Figure 12.14 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 12.15 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Figure 12.16 Mergers and Acquisitions: Country-wise Distribution
Figure 12.17 Mergers and Acquisitions: Continent-wise Distribution
Figure 12.18 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 12.19 Mergers and Acquisitions: Ownership Change Matrix
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 13.4 Recent Expansions: Distribution by Type of Cells Manufactured
Figure 13.5 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Figure 13.6 Recent Expansions: Distribution by Scale of Operation
Figure 13.7 Recent Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Figure 13.8 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 13.9 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Figure 13.10 Most Active Players: Distribution by Number of Expansions
Figure 13.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
Figure 13.12 Recent Expansions: Distribution by Year and Location of Manufacturing Facility
Figure 14.1 Big Pharma Initiatives: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Figure 14.2 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2017-2022
Figure 14.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 14.4 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 14.5 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 14.6 Big Pharma Initiatives: Distribution by Type of Cells Manufactured
Figure 14.7 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 14.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Number of Initiatives
Figure 14.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Type of Initiative
Figure 14.10 Big Pharma Initiatives: Distribution of Big Pharma Players by Type of Cells Manufactured
Figure 14.11 Big Pharma Initiatives: Distribution of Big Pharma Players by Scale of Operation
Figure 14.12 Harvey Ball Analysis: Big Pharma Initiatives Summary
Figure 14.13 Spider Web Analysis: Big Pharmaceutical Players
Figure 15.1 Installed Global Capacity of Industry Players for Cell Therapy Manufacturing (Number of Cleanrooms): Distribution by Company Size and Range of Installed Capacity
Figure 15.2 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 15.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Figure 15.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Figure 15.5 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 15.6 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 15.7 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 15.8 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Company Size
Figure 15.9 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 15.10 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 15.11 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 15.12 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 15.13 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Range of Installed Capacity
Figure 15.14 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Figure 15.15 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 15.16 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Range of Installed Capacity
Figure 15.17 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 15.18 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 16.1 Global Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Figure 16.2 Global Demand for Cell Therapies (Billion Cells), 2022-2035
Figure 16.3 Global Clinical Demand for Cell Therapies (Number of Patients), 2022-2035
Figure 16.4 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Figure 16.5 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Figure 16.6 Global Commercial Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Figure 16.7 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Figure 16.8 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Figure 17.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 18.1 Make versus Buy Decision Making Framework
Figure 18.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 19.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 19.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 19.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 19.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 19.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 19.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 20.1 Global Cell Therapy Manufacturing Market, 2022-2035 (USD Million)
Figure 20.2 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022-2035 (USD Million)
Figure 20.3 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.4 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Figure 20.5 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing, 2022-2035 (USD Million) 
Figure 20.6 Cell Therapy Manufacturing Market: Distribution by Region, 2022-2035 (USD Million)
Figure 20.7 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035 (USD Million)
Figure 20.8 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 20.9 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.10 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.11 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Figure 20.12 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Figure 20.13 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Figure 20.14 Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 20.15 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Figure 20.16 Global Commercial Scale Manufacturing Market for Stem Cell Therapies,2022-2035 (USD Million)
Figure 20.17 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Figure 20.18 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Figure 20.19 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035(USD Million)
Figure 20.20 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Typeof Therapy, 2022-2035 (USD Million)
Figure 20.21 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.22 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.23 Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 20.24 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 20.25 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Figure 20.26 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035(USD Million)
Figure 20.27 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.28 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 20.29 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Figure 20.30 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Figure 20.31 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Figure 21.1 Cell Therapy Manufacturing: Grid Analysis by Type of Cells Manufactured, Scale of Operation and Purpose of Manufacturing
Figure 21.2 Immune Cell Therapy Manufacturing: Logo Landscape
Figure 21.3 Stem Cell Therapy Manufacturing: Logo Landscape
Figure 21.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters
Figure 21.5 Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
Figure 22.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 22.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Partnerships and Collaborations
Figure 23.3 Concluding Remarks: Mergers and Acquisitions
Figure 23.4 Concluding Remarks: Recent Expansions
Figure 23.5 Concluding Remarks: Big Pharma Initiatives
Figure 23.6 Concluding Remarks: Capacity Analysis
Figure 23.7 Concluding Remarks: Demand Analysis
Figure 23.8 Concluding Remarks: Total Cost of Ownership
Figure 23.9 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 23.10 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2))
Figure 24.1 Survey Analysis: Distribution of Respondents by Type of Organization
Figure 24.2 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Figure 24.3 Survey Analysis: Distribution by Designation of Respondents
Figure 24.4 Survey Analysis: Distribution by Type of Cell Therapy
Figure 24.5 Survey Analysis: Distribution by Scale of Operation
Figure 24.6 Survey Analysis: Distribution by Source of Cells
Figure 24.7 Survey Analysis: Distribution by Type of Cell Culture System
Figure 24.8 Survey Analysis: Distribution by Availability of Fill / Finish Services

List Of Tables

Table 3.1 Cell-based Therapies: Key Applications
Table 3.2 Differences between Cell-based Therapies and Other Biotechnological Products
Table 3.3 Cell-based Therapies: Commercialized Products
Table 3.4 Assessments for Key Cell Therapy Manufacturing Steps
Table 3.5 Advantages and Disadvantages Associated with Centralized and Decentralized Manufacturing Models
Table 4.1 Cell Therapy Manufacturing: List of Industry Players
Table 4.2 Cell Therapy Manufacturing (Industry Players): Information on Type of Manufacturer
Table 4.3 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 4.4 Cell Therapy Manufacturing (Industry Players): Information on Source of Cells and Type of Cells Culture System Used
Table 4.5 Cell Therapy Manufacturing (Industry Players): Information on Scale of Operation
Table 4.6 Cell Therapy Manufacturing (Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 4.7 Cell Therapy Manufacturing: List of Non-Industry Players
Table 4.8 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Manufacturer
Table 4.9 Cell Therapy Manufacturing (Non-Industry Players): Information on Type of Cell Manufactured
Table 4.10 Cell Therapy Manufacturing (Non-Industry Players): Information on Source of Cells and Type of Cells Culture System Used
Table 4.11 Cell Therapy Manufacturing (Non-Industry Players): Information on Scale of Operation
Table 4.12 Cell Therapy Manufacturing (Non-Industry Players): Information on Manufacturing Capabilities / Services Offered
Table 5.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities /Certifications
Table 5.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities /Certifications
Table 5.3 Cell Therapy: Regulatory Considerations
Table 6.1 Cell Therapy Manufacturing: Roadmap for the US
Table 6.2 Cell Processing: Challenges and Strategies
Table 6.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 6.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 6.5 Standardization and Regulatory Support: Challenges and Strategies
Table 6.6 Workforce Development: Challenges and Strategies
Table 6.7 Supply Chain and Logistics: Challenges and Strategies
Table 6.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific EconomicCooperation (APEC)
Table 7.1 Cell Therapy Manufacturing: List of Automated and Closed Cell TherapyProcessing Systems
Table 7.2 Cell Therapy Manufacturing: Observed Changes in Scale-up Scenario while Switching from Manual to Automated Operations
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Overview of Manufacturing Facilities and Capabilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Charles River Laboratories: Company Overview
Table 8.5 Charles River Laboratories: Overview of Manufacturing Facilities and Capabilities
Table 8.6 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.7 KBI Biopharma: Company Overview
Table 8.8 KBI Biopharma: Overview of Manufacturing Facilities and Capabilities
Table 8.9 KBI Biopharma: Recent Developments and Future Outlook
Table 8.10 Thermo Fisher Scientific: Company Overview
Table 8.11 Thermo Fisher Scientific: Overview of Manufacturing Facilities and Capabilities
Table 8.12 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 8.13 BioNTech Innovative Manufacturing Services: Company Overview
Table 8.14 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Facilities and Capabilities
Table 8.15 BioNTech Innovative Manufacturing Services: Recent Developments and Future Outlook
Table 8.16 Cell and Gene Therapy Catapult: Company Overview
Table 8.17 Cell and Gene Therapy Catapult: Overview of Manufacturing Facilities and Capabilities
Table 8.18 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 8.19 Lonza: Company Overview
Table 8.20 Lonza: Overview of Manufacturing Facilities and Capabilities
Table 8.21 Lonza: Recent Developments and Future Outlook
Table 8.22 RoslinCT: Company Overview
Table 8.23 RoslinCT: Overview of Manufacturing Facilities and Capabilities
Table 8.24 RoslinCT: Recent Developments and Future Outlook
Table 8.25 Cell Therapies: Company Overview
Table 8.26 Cell Therapies: Overview of Manufacturing Facilities and Capabilities
Table 8.27 Cell Therapies: Recent Developments and Future Outlook
Table 8.28 FUJIFILM Cellular Dynamics: Company Overview
Table 8.29 FUJIFILM Cellular Dynamics: Overview of Manufacturing Facilities and Capabilities
Table 8.30 FUJIFILM Cellular Dynamics: Recent Developments and Future Outlook
Table 8.31 Minaris Regenerative Medicine: Company Overview
Table 8.32 Minaris Regenerative Medicine: Overview of Manufacturing Facilities and Capabilities
Table 8.33 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 8.34 MEDINET: Company Overview
Table 8.35 MEDINET: Overview of Manufacturing Facilities and Capabilities
Table 8.36 Nikon CeLL Innovation: Company Overview
Table 8.37 Nikon CeLL Innovation: Overview of Manufacturing Facilities and Capabilities
Table 8.38 WuXi AppTec: Company Overview
Table 8.39 WuXi AppTec: Overview of Manufacturing Facilities and Capabilities
Table 8.40 WuXi AppTec: Recent Developments and Future Outlook
Table 9.1 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 9.2 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
Table 9.3 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.4 Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.5 Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 9.6 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 9.7 Newcastle Cellular Therapies Facility: Overview of Manufacturing Facilities and Capabilities
Table 9.8 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 9.9 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine: Overview of Manufacturing Services and Capabilities
Table 9.10 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 10.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 10.2 CellCAN: Overview
Table 10.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 10.4 National Cell Manufacturing Consortium: Overview
Table 10.5 California’s Institute of Regenerative Medicine: Overview
Table 12.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
Table 12.2 Partnerships and Collaborations: Information on Type of Cells
Table 12.3 Partnerships and Collaborations: Information on Type of T Cells and Stem Cells
Table 12.4 Partnerships and Collaborations: Information on Scale of Operation
Table 12.5 Cell Therapy Manufacturing: List of Mergers and Acquisitions
Table 13.1 Cell Therapy Manufacturing: List of Expansions
Table 13.2 Recent Expansions: Information on Type of Cells Manufactured
Table 13.3 Recent Expansions: Information on Scale of Operation
Table 14.1 Big Pharma Initiatives: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
Table 14.2 Big Pharma Initiatives: Information on Type of Cells Manufactured
Table 14.3 Big Pharma Initiatives: Information on Scale of Operation
Table 15.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
Table 15.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
Table 15.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Table 15.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size
Table 15.5 Installed Global Capacity for Cell Therapy Manufacturing (in Terms of Number of Cleanrooms): Average Capacity for Non-Industry Players
Table 15.6 Installed Global Capacity for Cell Therapy Manufacturing (in Terms of Cleanroom Area, Sq. ft.): Average Capacity for Non-Industry Players
Table 17.1 Costs Associated with the Manufacturing of Stem Cell Therapies
Table 17.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
Table 17.3 T-cell Immunotherapies: Expert Opinions on Pricing
Table 17.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 19.1 Total Cost of Ownership: Sample Dataset
Table 20.1 Active Clinical Studies for Autologous Cell Therapies
Table 20.2 Active Clinical Studies for Autologous Cell Therapies: Distribution by Patients Enrolled
Table 20.3 Active Clinical Studies for Allogeneic Cell Therapies
Table 20.4 Active Clinical Studies for Allogeneic Cell Therapies: Distribution by Patients Enrolled
Table 24.1 Survey Analysis: Overview of Respondents
Table 24.2 Survey Analysis: Designations and Seniority Levels
Table 24.3 Survey Analysis: Type of Cell Therapy
Table 24.4 Survey Analysis: Scale of Operation
Table 24.5 Survey Analysis: Source of Cells
Table 24.6 Survey Analysis: Cell Culture System Used
Table 24.7 Survey Analysis: Availability of Fill / Finish Services
Table 25.1 RoslinCT: Key Highlights
Table 25.2 Discovery Life Sciences: Key Highlights
Table 25.3 Glycostem Therapeutics: Key Highlights
Table 25.4 Bio Elpida: Key Highlights
Table 25.5 Gracell Biotechnologies: Key Highlights
Table 25.6 Kadimastem: Key Highlights
Table 25.7 RoslinCT: Key Highlights
Table 25.8 University of Minnesota: Key Highlights
Table 25.8 Lion TCR: Key Highlights
Table 25.10 Center for Commercialization of Cancer Immunotherapy (C3i): Key Highlights
Table 25.11 Yposkesi: Key Highlights
Table 25.12 CiMaas: Key Highlights
Table 26.1 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size
Table 26.2 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment
Table 26.3 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 26.4 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 26.5 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Location of Headquarters
Table 26.6 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment and Location of Headquarters
Table 26.7 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Region-wise)
Table 26.8 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Manufacturing Facilities (Country-wise)
Table 26.9 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Manufacturer
Table 26.10 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Table 26.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cells Manufactured
Table 26.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 26.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 26.14 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Type of Cells Manufactured
Table 26.15 Cell Therapy Manufacturing (Industry Players): Distribution by Location of Headquarters and Type of Cells Manufactured
Table 26.16 Cell Therapy Manufacturing (Industry Players): Distribution by Source of Cells
Table 26.17 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cells Manufactured and Source of Cells
Table 26.18 Cell Therapy Manufacturing (Industry Players): Distribution by Scale of Operation
Table 26.19 Cell Therapy Manufacturing (Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 26.20 Cell Therapy Manufacturing (Industry Players): Distribution by Company Size and Services Offered
Table 26.21 Cell Therapy Manufacturing (Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Table 26.22 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size
Table 26.23 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment
Table 26.24 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Region-wise)
Table 26.25 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters (Country-wise)
Table 26.26 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Location of Headquarters
Table 26.27 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment and Location of Headquarters
Table 26.28 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.29 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.30 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Manufacturer
Table 26.31 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Manufacturer
Table 26.32 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cells Manufactured
Table 26.33 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Immune Cell Manufactured
Table 26.34 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Stem Cell Manufactured
Table 26.35 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Type of Cells Manufactured
Table 26.36 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Location of Headquarters and Type of Cells Manufactured
Table 26.37 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Source of Cells
Table 26.38 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Type of Cells Manufactured and Source of Cells
Table 26.39 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Scale of Operation
Table 26.40 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Manufacturing Capabilities / Services Offered
Table 26.41 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Organization Size and Services Offered
Table 26.42 Cell Therapy Manufacturing (Non-Industry Players): Distribution by Year of Establishment, Location of Headquarters and Services Offered
Table 26.43 Clinical Trial Analysis: Distribution by Trial Registration Year, 2019-2022
Table 26.44 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, 2019-2022
Table 26.45 Clinical Trial Analysis: Distribution by Trial Status
Table 26.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 26.47 Clinical Trial Analysis: Distribution by Trial Phase
Table 26.48 Clinical Trial Analysis: Distribution of Number of Trials by Enrolled Patient Population and Trial Phase
Table 26.49 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 26.50 Clinical Trial Analysis: Distribution by Patient Segment
Table 26.51 Clinical Trial Analysis: Distribution by Study Design
Table 26.52 Most Active Industry Players: Distribution by Number of Registered Trials
Table 26.53 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 26.54 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geographical Location
Table 26.55 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geographical Location
Table 26.56 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 26.57 Partnerships and Collaborations: Distribution by Type of Partnership
Table 26.58 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 26.59 Partnerships and Collaborations: Distribution by Type of Cells
Table 26.60 Heat Map: Distribution by Year and Type of Cells
Table 26.61 Partnerships and Collaborations: Distribution by Type of T-Cell
Table 26.62 Partnerships and Collaborations: Distribution by Type of Stem Cell
Table 26.63 Partnerships and Collaborations: Distribution by Scale of Operation
Table 26.64 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Table 26.65 Partnerships and Collaborations: Country-wise Distribution
Table 26.66 Partnerships and Collaborations: Continent-wise Distribution
Table 26.67 Most Active Players: Distribution by Number of Partnerships
Table 26.68 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022 (till June)
Table 26.69 Mergers and Acquisitions: Distribution by Type of Agreement
Table 26.70 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Table 26.71 Mergers and Acquisitions: Country-wise Distribution
Table 26.72 Mergers and Acquisitions: Continent-wise Distribution
Table 26.73 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 26.74 Mergers and Acquisitions: Ownership Change Matrix
Table 26.75 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 26.76 Recent Expansions: Distribution by Type of Expansion
Table 26.77 Recent Expansions: Distribution by Year and Type of Expansion
Table 26.78 Recent Expansions: Distribution by Type of Cells Manufactured
Table 26.79 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Table 26.80 Recent Expansions: Distribution by Scale of Operation
Table 26.81 Recent Expansions: Distribution by Location of Manufacturing Facility (Region-wise)
Table 26.82 Recent Expansions: Distribution by Location of Manufacturing Facility (Country-wise)
Table 26.83 Recent Expansions: Distribution by Type of Expansion and Location of Manufacturing Facility
Table 26.84 Most Active Players: Distribution by Area of Expansion (in sq ft)
Table 26.85 Big Pharma Initiatives: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Table 26.86 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative, 2017-2022
Table 26.87 Big Pharma Initiatives: Distribution by Type of Initiative
Table 26.88 Big Pharma Initiatives: Distribution by Type of Partnership
Table 26.89 Big Pharma Initiatives: Distribution by Type of Expansion
Table 26.90 Big Pharma Initiatives: Distribution by Type of Cells Manufactured
Table 26.91 Big Pharma Initiatives: Distribution by Scale of Operation
Table 26.92 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Number of Initiatives
Table 26.93 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Type of Initiative
Table 26.94 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size
Table 26.95 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Table 26.96 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 26.97 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Table 26.98 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 26.99 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size
Table 26.100 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation
Table 26.101 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Location of Manufacturing Facility
Table 26.102 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Company Size and Location of Manufacturing Facility
Table 26.103 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 26.104 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Scale of Operation
Table 26.105 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 26.106 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Scale of Operation
Table 26.107 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (in terms of Cleanroom Area, Sq. ft.): Distribution by Location of Manufacturing Facility
Table 26.108 Global Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Table 26.109 Global Demand for Cell Therapies (Billion Cells), 2022-2035
Table 26.110 Global Clinical Demand for Cell Therapies, 2022-2035 (Number of Patients)
Table 26.111 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Table 26.112 Global Clinical Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Table 26.113 Global Commercial Demand for Cell Therapies (in terms of Number of Patients), 2022-2035
Table 26.114 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Type of Cell Therapy, 2022-2035
Table 26.115 Global Commercial Demand for Cell Therapies (in terms of Number of Patients): Distribution by Geographical Location, 2022-2035
Table 26.116 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Table 26.117 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 26.118 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 26.119 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations,Y1-Y20: Distribution by OPEX(USD Million)
Table 26.120 Global Cell Therapy Manufacturing Market, 2022-2035 (USD Million)
Table 26.121 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy,2022-2035 (USD Million)
Table 26.122 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 26.123 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022-2035 (USD Million)
Table 26.124 Cell Therapy Manufacturing Market: Distribution by Purpose of Manufacturing,2022-2035 (USD Million) 
Table 26.125 Cell Therapy Manufacturing Market: Distribution by Region, 2022-2035 (USDMillion)
Table 26.126 Global Commercial Scale Manufacturing Market for T-cell Therapies, 2022-2035 (USD Million)
Table 26.127 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byType of Therapy, 2022-2035 (USD Million)
Table 26.128 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.129 Commercial Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.130 Global Commercial Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Table 26.131 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Table 26.132 Commercial Scale Manufacturing Market for NK Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Table 26.133 Global Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 26.134 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Table 26.135 Global Commercial Scale Manufacturing Market for Stem Cell Therapies,2022-2035 (USD Million)
Table 26.136 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Source of Cells, 2022-2035 (USD Million)
Table 26.137 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distributionby Region, 2022-2035 (USD Million)
Table 26.138 Global Clinical Scale Manufacturing Market for T-cell Therapies, 2022-2035(USD Million)
Table 26.139 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution by Typeof Therapy, 2022-2035 (USD Million)
Table 26.140 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.141 Clinical Scale Manufacturing Market for T-cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.142 Global Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 26.143 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 26.144 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Region, 2022-2035 (USD Million)
Table 26.145 Global Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035(USD Million)
Table 26.146 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.148 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.149 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 26.150 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.151 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.152 Survey Analysis: Distribution of Respondents by Type of Organization
Table 26.153 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Table 26.154 Survey Analysis: Distribution by Designation of Respondents
Table 26.155 Survey Analysis: Distribution by Type of Cell Therapies
Table 26.156 Survey Analysis: Distribution by Scale of Operation
Table 26.157 Survey Analysis: Distribution by Source of Cells
Table 26.158 Survey Analysis: Distribution by Availability of Fill / Finish Services                                                                                                                                Table 26.159 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.160 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.161 Global Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 26.162 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution bySource of Cells, 2022-2035 (USD Million)
Table 26.163 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution byRegion, 2022-2035 (USD Million)
Table 26.164 Cell Therapy Manufacturing: Grid Analysis by Type of Cells Manufactured, Scale of Operation and Purpose of Manufacturing
Table 26.165 Survey Analysis: Distribution of Respondents by Type of Organization
Table 26.166 Survey Analysis: Distribution of Respondents by Location of Manufacturing Facility
Table 26.167 Survey Analysis: Distribution by Designation of Respondents
Table 26.168 Survey Analysis: Distribution by Type of Cell Therapies
Table 26.169 Survey Analysis: Distribution by Scale of Operation
Table 26.170 Survey Analysis: Distribution by Source of Cells
Table 26.171 Survey Analysis: Distribution by Type of Cells Culture System
Table 26.172 Survey Analysis: Distribution by Availability of Fill / Finish Services

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

1. 3SBio
2. 3P Biopharmaceuticals
3. A*STAR’s Bioprocessing Technology Institute (BTI)
4. A2 Biotherapeutics
5. A2 Healthcare
6. Abeona Therapeutics
7. Accellta
8. Achilles Therapeutics
9. Adaptate Biotherapeutics
10. Adaptimmune Therapeutics
11. Adva Biotechnology
12. Advance BioScience Laboratories (ABL)
13. Advanced Cell Therapy Laboratory (ACTL)
14. Advanced Regenerative Manufacturing Institute
15. Advent Bioservices
16. AGC Biologics
17. Agilent Technologies
18. Aglaris
19. Akron Biotech
20. Alberta Cell Therapy Manufacturing (ACTM)
21. Allele Biotechnology and Pharmaceuticals
22. Allogene Therapeutics
23. Anemocyte
24. anicells
25. Anterogen
26. Antion Biosciences
27. apceth Biopharma
28. Appia Bio
29. ArchiMed
30. Argos Therapeutics
31. Arsenal Biosciences
32. Artiva Biotherapeutics
33. Asahi Glass
34. Ascend Gene and Cell Therapies
35. Aseptic Technologies
36. Aspire Health Science
37. Astellas Pharma
38. Asterias Biotherapeutics
39. Astero Bio
40. ASTRAVEUS
41. Asymptote
42. Atara Biotherapeutics
43. Athersys
44. Austrianova
45. Autolus
46. Avalon GloboCare
47. Avectas
48. Avery Therapeutics
49. Bayer
50. Be Biopharma
51. Be The Match BioTherapies
52. Bellicum Pharmaceuticals
53. Bio Elpida
54. BioCardia
55. BioCentriq
56. Bioinova
57. BioNTech
58. BioRestorative Therapies
59. BioTherapeutics Unit, Netherlands Cancer Institute
60. bluebird bio
61. BlueRock Therapeutics
62. Bone Therapeutics
63. Boston Children's Hospital
64. Boyalife
65. BrainStorm Cell Therapeutics
66. Brammer Bio
67. BriaCell Therapeutics
68. Bristol Myers Squibb
69. Centre for Commercialization of Cancer Immunotherapy (C3i)
70. Caladrius Biosciences
71. CANCER RESEARCH TECHNOLOGY (CRT)
72. CancerRop
73. Capricor Therapeutics
74. CariCord
75. Carisma Therapeutics
76. CARsgen Therapeutics
77. Cartesian Therapeutics
78. Cartexell
79. CaseBioscience
80. Catalent
81. Catapult Therapy TCR (Acquired by Cell Medica)
82. Cbio
83. Cedars-Sinai Biomanufacturing Center
84. Celgene
85. Cell and Gene Therapy Catapult
86. Cell and Gene Therapy Laboratory, Children’s Hospital of Philadelphia
87. Cell Medica
88. Cell Therapies
89. Cell Therapies Core, Moffitt Cancer Center
90. Cell Therapy and Regenerative Medicine, University of Utah
91. Regenerative Medicine Center, Utrecht University
92. Cell Therapy Manufacturing Facility, MedStar Georgetown University Hospital
93. Cell Therapy Suite, University of Birmingham
94. Cellaïon
95. Cellares
96. Cellatoz Therapeutics
97. Cell-Easy
98. Cellectis
99. Cellevolve Bio
100. Cellex Cell Professionals
101. CELLforCURE
102. Cellin Technologies
103. Cellino
104. Cellipont Bioservices
105. Cellistic
106. Cell Manufacturing and Production
107. CellPoint
108. Cells for Sight Stem Cell Therapy Research Unit, University College London
109. Cellular Biomedicine Group
110. Cellular Therapy Core, Sidney Kimmel Comprehensive Cancer Center
111. Cellular Therapy Core, University of Texas
112. Cellular Therapy Integrated Services, Case Western Reserve University
113. Celonic
114. Celularity
115. Celyad Oncology
116. Center for Biomedical Engineering and Advanced Manufacturing, McMaster
117. Center for Breakthrough Medicines
118. Center for Cellular Immunotherapies
119. Center for Cell and Gene Therapy, Baylor College of Medicine
120. Center for International Blood and Marrow Transplant Research
121. Centre for Biological Engineering, Loughborough University
122. Centre for Cell and Vector Production
123. Centre for Cell Manufacturing Ireland, NUI Galway
124. Centre for Stem Cell Research (CSCR), Christian Medical College
125. Century Therapeutics
126. Cesca Therapeutics
127. cGMPnow
128. CHA Biolab
129. CHA Biotech
130. Charles River Laboratories
131. Chart Industries
132. Chiesi Farmaceutici
133. Children's GMP, St. Jude Children's Research Hospital
134. Children's National Hospital
135. Chimeric Therapeutics
136. China Life Health Industry Group
137. China Regenerative Medicine International
138. IQVIA Cell And Gene Therapy Center
139. City of Hope
140. Clean Cells
141. Clinical Biomanufacturing Facility, University of Oxford
142. Clinical Cell and Vaccine Production Facility
143. CMIC Group
144. CO.DON
145. Cogent Biosciences
146. Cognate BioServices
147. CoImmune
148. CCRM
149. Comprehensive Cell Solutions™
150. Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF)
151. Cook MyoSite
152. CPI
153. Creative Biolabs
154. Crescendo Biologics
155. CRISPR Therapeutics
156. Cryoport
157. CSIRO
158. CTM CRC
159. CUORiPS
160. Cynata Therapeutics
161. Cytiva
162. Cytonet
163. Cytosen Therapeutics
164. Cytovance Biologics
165. Daiichi Sankyo
166. Dendreon Pharmaceuticals
167. David and Etta Jonas Center for Cellular Therapy, UChicago Medicine
168. DCPrime
169. Deep Science Ventures
170. Delphi Genetics
171. Dendreon
172. Draper
173. Duke-NUS Medical School
174. ElevateBio
175. Emory Cellular and Immunotherapy Core (ExCITE)"
176. Empirica Therapeutics (Acquired by Century Therapeutics)
177. ENABLE SPARKS Cells
178. ERYTECH Pharma
179. Esco Aster
180. Esco VacciXcell
181. EUFETS
182. Eutilex
183. Exacis Biotherapeutics
184. Excellos
185. ExCellThera
186. eXmoor Pharma
187. Expression Therapeutics
188. FamiCord
189. Fate Therapeutics
190. Flaskworks (Acquired by Northwest Biotherapeutics)
191. FloDesign Sonics
192. Forecyte Bio
193. Formula Pharmaceuticals
194. Fosun Pharma
195. Fraunhofer Institute for Cell Therapy and Immunology
196. Fred Hutchinson Cancer Research Center
197. French Blood Agency
198. Fresenius Kabi
199. Froceth
200. FUJIFILM Cellular Dynamics
201. FUJIFILM Diosynth Biotechnologies
202. FutureGen Biopharm
203. Gamida Cell
204. GammaDelta Therapeutics
205. Gates Biomanufacturing Facility
206. GC Cell
207. GE Healthcare Life Sciences
208. GenCure
209. Gene and Cell Therapy Lab, Institute of Translational Health Sciences
210. Genentech
211. Genexine
212. Genezen
213. GenIbet Biopharmaceuticals
214. German Red Cross Blood Donor Service
215. Ghent University
216. GI Cell
217. Gilead Sciences
218. GlaxoSmithKline
219. Glycostem Therapeutics
220. Glycotope
221. GPB Scientific
222. Gracell Biotechnologies
223. Great Ormond Street Hospital Cellular Therapy Laboratories, University College of London
224. GX Acquisition
225. H. Lee Moffitt Cancer Center and Research Institute
226. Haemonetics
227. Harvard University Stem Cell Institute
228. Health Sciences Authority (HSA)
229. Hebei Senlang Biotechnology
230. Helixmith
231. Hemostemix
232. Histocell
233. Hitachi Chemical
234. Holostem Terapie Avanzate
235. Human Islet and Cellular Transplant Facility
236. August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
237. I Peace
238. IASO Biotherapeutics
239. Immatics
240. Immuneel Therapeutics
241. ImmunityBio
242. Immunomic Therapeutics
243. Immunovative Therapies
244. Immusoft
245. Imugene
246. IncoCell Tianjin
247. Indapta Therapeutics
248. Innovative Cellular Therapeutics
249. Instil Bio
250. Intellia Therapeutics
251. Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
252. International Stem Cell Corporation
253. Invetech
254. Iovance Biotherapeutics
255. IsoPlexis
256. Ixaka
257. Janssen Biotech
258. Janssen Pharmaceuticals
259. Japan Tissue Engineering
260. Jiuzhitang Maker Cell Technology
261. John Goldman Centre for Cellular Therapy, Imperial College London
262. Juno Therapeutics
263. JW CreaGene
264. JW Therapeutics
265. Kadimastem
266. Kangstem Biotech
267. Karolinska Institutet
268. Kawasaki Heavy Industries
269. KBI Biopharma
270. Kemwell Biopharma
271. Kiadis Pharma
272. King's Clinical Research Facility
273. Kite Pharma
274. KOLON Biotech
275. Krembil Cell Facility, St. Michael’s Hospital
276. KSQ Therapeutics
277. Laboratory for Cell and Gene Medicine, University of Stanford
278. Legend Biotech
279. Limula
280. Lineage Cell Therapeutics
281. Lion TCR
282. Longeveron
283. Lonza
284. Lorem Cytori
285. LumaCyte
286. Lyell Immunopharma
287. Lykan Bioscience
288. Lymphotec
289. Marker Therapeutics
290. Massachusetts General Hospital
291. MaSTherCell
292. Matica Biotechnology
293. MaxiVAX
294. Human Cellular Therapy Laboratory, Mayo Clinic
295. MD Anderson Cancer Center
296. Medace
297. Medeor Therapeutics
298. Medera
299. Medigene
300. MEDINET
301. MEDIPOST
302. MedTherapy
303. Membio
304. Memorial Sloan Kettering Cancer Center
305. Merck
306. Mesoblast
307. MicrofluidX
308. Midwest Stem Cell Therapy Center, University of Kansas Medical Center
309. Miltenyi Biotec
310. Minaris Regenerative Medicine
311. MiNK Therapeutics
312. Minovia Therapeutics
313. Molecular and Cellular Therapeutics, University of Minnesota
314. MolMed
315. Mustang Bio
316. Nagoya University
317. Nanjing Cenbest
318. KAEDI
319. NantKwest
320. National Cancer Institute
321. National Eye Institute
322. National Resilience
323. Ncardia
324. Neon Therapeutics
325. NeoProgen
326. New Jersey Innovation Institute (NJII)
327. Newcastle Advanced Therapies
328. NextCell Pharma
329. NHS Blood and Transplant
330. NIHR Clinical Research Facility (CRF) at Guy’s and St Thomas’
331. Nikon CeLL innovation
332. Nippon Shinyaku
333. Nipro
334. NiSCELL
335. Nkarta
336. NKGen Biotech (Formerly known as NKMax America)
337. Nohla Therapeutics
338. Noile-Immune Biotech
339. Northwest Biotherapeutics
340. Notch Therapeutics
341. Novadip Biosciences
342. Novartis
343. Novartis Gene Therapies
344. Novex Innovations
345. Novo Nordisk
346. ObiO Technology
347. Octane Biotech
348. ONK Therapeutics
349. Ono Pharmaceutical
350. Ontario Institute for Regenerative Medicine
351. Opexa Therapeutics
352. Orca Bio
353. OrganaBio
354. Orgenesis
355. Ori Biotech
356. Ospedale Pediatrico Bambino Gesù
357. OSPIN
358. Overland Pharmaceuticals
359. Ovizio Imaging Systems
360. Oxford MEStar
361. OXGENE
362. Pall Corporation
363. PanCryos
364. Parker Institute for Cancer Immunotherapy
365. PCT
366. Performance Cell Manufacturing
367. PersonGen BioTherapeutics
368. PharmaBio
369. PharmaCell
370. Pharmicell
371. pHion Therapeutics
372. Pierre Fabre
373. Pluristem Therapeutics
374. Precision BioSciences
375. Promethera Biosciences
376. Provia Laboratories
377. Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
378. QIMR Berghofer Medical Research Institute
379. QuaCell Biotechnology
380. Quell Therapeutics
381. Rayne Cell Therapy Suite
382. Recipharm
383. Regeneus
384. ReNeuron
385. Rentschler ATMP
386. Rentschler Biopharma
387. Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
388. Rexgenero
389. RheinCell Therapeutics (Acquired by Catalent)
390. Rivaara Immune
391. Riyadh Pharma
392. Robertson Clinical and Translational Cell Therapy, Duke University
393. RoosterBio
394. RoslinCT
395. Centre for Cell and Gene Tissue Therapeutics, Royal Free Hospital London
396. Rubius Therapeutics
397. Rutgers Cancer Institute of New Jersey
398. S.Biomedics
399. Saint-Gobain
400. SAKARTA
401. Sana Biotechnology
402. SanBio
403. Sangamo Therapeutics
404. Sanpower
405. Sartorius
406. SCG Cell Therapy
407. Scinogy
408. Scinus Cell Expansion
409. SCM Lifescience
410. Scottish National Blood Transfusion Service
411. SCTbio
412. Secarna Pharmaceuticals
413. Senti Biosciences
414. Servier
415. Shanghai Ucardi Biomedical Technology
416. Sheba Medical Center
417. Shibuya
418. Shinshu University
419. Shoreline Biosciences
420. SingCell
421. Skeletal Cell Therapy Support (Acquired by Catalent)
422. Sorrento Therapeutics
423. SOTIO
424. Southwest Research Institute
425. S-RACMO
426. Stanford University School of Medicine
427. Stem Cell Institute
428. STEMCELL Technologies
429. Stemedica Cell Technologies
430. Stemmatters
431. Stempeutics Research
432. Sumitomo Dainippon Pharma
433. Suzhou Porton Biologics
434. Sydney Cell and Gene Therapy
435. Syngen Biotech
436. Takara Bio
437. Takeda
438. TapImmune
439. TC BioPharm
440. TCR2 Therapeutics
441. TCRCure Biopharma
442. Terumo Blood and Cell Technologies
443. Tessa Therapeutics
444. Tevogen Bio
445. The Discovery Labs Center for Breakthrough Medicines
446. The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
447. The Netherlands Cancer Institute
448. The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen)
449. The Ottawa Hospital Research Institute
450. The Philip S. Orsino Facility for Cell Therapy, Princess Margaret Hospital
451. The University of Texas MD Anderson Cancer Center
452. Therabest
453. Theragent
454. Therapeutic Cell Production Core, Seattle Children's Hospital
455. Therapeutic Cell Production Facility, Roswell Park Comprehensive Cancer Center
456. Thermo Fisher Scientific
457. ThermoGenesis
458. TiGenix
459. Tissue Genesis
460. T-knife
461. Tmunity Therapeutics
462. TrakCel
463. Treadwell Therapeutics
464. TreeFrog Therapeutics
465. Triumvira Immunologics
466. Trizell
467. TVAX Biomedical
468. TxCell
469. UC Davis GMP Laboratory
470. UCLA Human Gene and Cell Therapy
471. Universal Cells
472. University Hospital Basel
473. University of Chicago Medicine
474. University of North Carolina Lineberger Comprehensive Cancer Center
475. Upstate Stem Cell cGMP Facility (USCGF), University of Rochester
476. UW Program for Advanced Cell Therapy (PACT)
477. Vanrx Pharmasystems
478. Vecura
479. Vericel
480. Vineti
481. Vinta Bio
482. Viscofan BioEngineering
483. VivaBioCell
484. Waisman Biomanufacturing
485. Wilson Wolf Manufacturing
486. Wugen
487. WuXi Advanced Therapies
488. Xintela
489. Zelluna Immunotherapy